Annals of Oncology Advance Access published online on November 28, 2005
Annals of Oncology, doi:10.1093/annonc/mdj078
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Medical Oncology Division, Silvestrini Hospital, Perugia, Italy
* To whom correspondence should be addressed. Background: In the late 1990s, several professional organizations convened antiemetic guideline groups and published the findings of these expert panels. Each of these documents was based on analyses of the available published trials and provided nearly similar recommendations. Nonetheless, small differences in emetic risk categories and treatment recommendations led to confusion in antiemetics selection. With the emergence of new findings and agents since the guidelines were initially published, many of the oncology professional societies have updated the antiemetic guidelines. Materials and methods: A literature review up to March 2004 was carried out using MEDLINE with evaluation of the evidence by an expert panel composed of 23 oncology professionals in clinical medicine, medical oncology, radiation oncology, oncology nursing, statistics, pharmacy, medical policy and decision making, and pharmacology. The experts represented nine oncology professional societies and came from 11 different countries on four continents. Results: Recommendations on antiemetic regimens to prevent emesis induced by high, moderate, low and minimal risk chemotherapy were suggested as well as management of anticipatory emesis. Furthermore, recommendations for refractory emesis, emesis induced by high-dose chemotherapy and radiotherapy and for antiemetics in children receiving chemotherapy were elaborated. Conclusions: Recommendations about antiemetic prophylaxis in patients receiving treatment with chemo- and radiotherapy have been updated by representatives of nine oncological organizations.
Received October 6, 2005
Accepted October 17, 2005
review
Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference
The Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) 1 *
The Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC), E-mail: roila.fausto{at}libero.it
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. Roila, J. Rolski, R. Ramlau, M. Dediu, M. W. Russo, R. R. Bandekar, and S. M. Grunberg Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting Ann. Onc., November 1, 2009; 20(11): 1867 - 1873. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Maemondo, N. Masuda, I. Sekine, K. Kubota, Y. Segawa, M. Shibuya, F. Imamura, N. Katakami, T. Hida, S. Takeo, et al. A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy Ann. Onc., November 1, 2009; 20(11): 1860 - 1866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Adamsen, M. Quist, C. Andersen, T. Moller, J. Herrstedt, D. Kronborg, M. T Baadsgaard, K. Vistisen, J. Midtgaard, B. Christiansen, et al. Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial BMJ, October 20, 2009; 339(oct13_1): b3410 - b3410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Hesketh Penny Wise, Dollar Foolish Approach to Antiemetic Use May Compromise Patient Care J. Oncol. Pract, September 1, 2009; 5(5): 221 - 222. [Full Text] [PDF]
|
|
|
|
 |
|
 K. TAGUCHI, H. IIHARA, M. ISHIHARA, Y. KOMORI, K. TANIZAWA, K. MATSUURA, and Y. ITOH Comparison of Antiemetic Efficacy between Single and Repeated Treatments with a 5-HT3 Receptor Antagonist in Breast Cancer Patients with High-risk Emetogenic Chemotherapy Anticancer Res, May 1, 2009; 29(5): 1721 - 1725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Herrstedt, F. Roila, and On behalf of the ESMO Guidelines Working Group Chemotherapy-induced nausea and vomiting: ESMO Clinical Recommendations for prophylaxis Ann. Onc., May 1, 2009; 20(suppl_4): iv156 - iv158. [Full Text] [PDF]
|
|
|
|
 |
|
 V. Shih, H. S. Wan, and A. Chan Clinical Predictors of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer Patients Receiving Adjuvant Doxorubicin and Cyclophosphamide Ann. Pharmacother., March 1, 2009; 43(3): 444 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Naeim, S. M. Dy, K. A. Lorenz, H. Sanati, A. Walling, and S. M. Asch Evidence-Based Recommendations for Cancer Nausea and Vomiting J. Clin. Oncol., August 10, 2008; 26(23): 3903 - 3910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Hesketh Chemotherapy-Induced Nausea and Vomiting N. Engl. J. Med., June 5, 2008; 358(23): 2482 - 2494. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Jordan, C. Sippel, and H.-J. Schmoll Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present, and Future Recommendations Oncologist, September 1, 2007; 12(9): 1143 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gurpide, B. Sadaba, S. Martin-Algarra, J. R. Azanza, J. M. Lopez-Picazo, M. A. Campanero, J. P. Cabello, I. Gil-Aldea, S. de la Cruz, V. F. Gallego, et al. Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients Treated with Platinum-Based Chemotherapy Oncologist, September 1, 2007; 12(9): 1151 - 1155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kerr Now the New Year reviving old desires Ann. Onc., January 1, 2007; 18(1): 3 - 3. [Full Text] [PDF]
|
|
|
|
|
|
M. G. Kris, P. J. Hesketh, M. R. Somerfield, P. Feyer, R. Clark-Snow, J. M. Koeller, G. R. Morrow, L. W. Chinnery, M. J. Chesney, R. J. Gralla, et al. American Society of Clinical Oncology Guideline for Antiemetics in Oncology: Update 2006 J. Clin. Oncol., June 20, 2006; 24(18): 2932 - 2947. [Abstract] [Full Text] [PDF]
|
|